Search

Your search keyword '"Lalli, Luca"' showing total 112 results
Start Over Author "Lalli, Luca"
112 results on '"Lalli, Luca"'

1. Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy

Author

Pasquali, Sandro, Vallacchi, Viviana, Lalli, Luca, Collini, Paola, Barisella, Marta, Romagosa, Cleofe, Bague, Silvia, Coindre, Jean Michel, Dei Tos, Angelo Paolo, Palmerini, Emanuela, Quagliuolo, Vittorio, Martin-Broto, Javier, Lopez-Pousa, Antonio, Grignani, Giovanni, Blay, Jean-Yves, Beveridge, Robert Diaz, Casiraghi, Elena, Brich, Silvia, Renne, Salvatore Lorenzo, Bergamaschi, Laura, Vergani, Barbara, Sbaraglia, Marta, Casali, Paolo Giovanni, Rivoltini, Licia, Stacchiotti, Silvia, and Gronchi, Alessandro

Published
2024
Full Text
View/download PDF

2. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27

Author

Stellato, Marco, Buti, Sebastiano, Maruzzo, Marco, Bassanelli, Maria, Bersanelli, Melissa, Napoli, Marilena Di, Dionese, Michele, Fanelli, Martina, Filippi, Roberto, Fotia, Giuseppe, Galli, Luca, Grillone, Francesco, Maffezzoli, Michele, Maiorano, Brigida Anna, Nasso, Cecilia, Rebuzzi, Sara Elena, Lalli, Luca, Roviello, Giandomenico, Sorarù, Mariella, Vincenzi, Bruno, Procopio, Giuseppe, and Verzoni, Elena

Published
2024
Full Text
View/download PDF

3. Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes

Author

Cuccu, Ilaria, Raspagliesi, Francesco, Malzoni, Mario, Vizza, Enrico, Papadia, Andrea, Di Donato, Violante, Giannini, Andrea, De Iaco, Pierandrea, Perrone, Anna Myriam, Plotti, Francesco, Angioli, Roberto, Casarin, Jvan, Ghezzi, Fabio, Cianci, Stefano, Vizzielli, Giuseppe, Restaino, Stefano, Petrillo, Marco, Sorbi, Flavia, Multinu, Francesco, Schivardi, Gabriella, De Vitis, Luigi Antonio, Falcone, Francesca, Lalli, Luca, Berretta, Roberto, Mueller, Michael D., Tozzi, Roberto, Chiantera, Vito, Benedetti Panici, Pierluigi, Fanfani, Francesco, Scambia, Giovanni, and Bogani, Giorgio

Published
2024
Full Text
View/download PDF

4. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Author

Zattarin, Emma, Presti, Daniele, Mariani, Luigi, Sposetti, Caterina, Leporati, Rita, Menichetti, Alice, Corti, Chiara, Benvenuti, Chiara, Fucà, Giovanni, Lobefaro, Riccardo, Ligorio, Francesca, Provenzano, Leonardo, Vingiani, Andrea, Del Vecchio, Marta, Griguolo, Gaia, Sirico, Marianna, Bernocchi, Ottavia, Marra, Antonio, Zagami, Paola, Agostinetto, Elisa, Jacobs, Flavia, Di Mauro, Pierluigi, Esposito, Andrea, Giorgi, Carlo Alberto, Lalli, Luca, Boldrini, Laura, Giacchetti, Pier Paolo Berton, Schianca, Ambra Carnevale, Guarneri, Valentina, Pedersini, Rebecca, Losurdo, Agnese, Zambelli, Alberto, Generali, Daniele, Criscitiello, Carmen, Curigliano, Giuseppe, Pruneri, Giancarlo, de Braud, Filippo, Dieci, Maria Vittoria, and Vernieri, Claudio

Published
2023
Full Text
View/download PDF

5. Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles

Author

Vergani, Elisabetta, Busico, Adele, Dugo, Matteo, Devecchi, Andrea, Valeri, Barbara, Cossa, Mara, Di Guardo, Lorenza, De Cecco, Loris, Feltrin, Erika, Valle, Giorgio, Deho, Paola, Frigerio, Simona, Lalli, Luca, Gallino, Gianfrancesco, Del Vecchio, Michele, Santinami, Mario, Pruneri, Giancarlo, Tamborini, Elena, Rivoltini, Licia, Sensi, Marialuisa, Vallacchi, Viviana, and Rodolfo, Monica

Published
2022
Full Text
View/download PDF

7. Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy...

Author

Mereu, Alessandro, Salsetta, Jeannette, Lalli, Luca, Squarcina, Paola, Banfi, Cristina, Sgambelluri, Francesco, Mortarini, Roberta, Huber, Veronica, Stellato, Marco, Raggi, Daniele, Guadalupi, Valentina, Claps, Melanie, Bottiglieri, Achille, Walter, Ferrari Bravo, Calareso, Giuseppina, Alessi, Alessandra, Procopio, Giuseppe, Necchi, Andrea, Rivoltini, Licia, and Giannatempo, Patrizia

Published
2024
Full Text
View/download PDF

9. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

Author

Huber, Veronica, Vallacchi, Viviana, Fleming, Viktor, Hu, Xiaoying, Cova, Agata, Dugo, Matteo, Shahaj, Eriomina, Sulsenti, Roberta, Vergani, Elisabetta, Filipazzi, Paola, De Laurentiis, Angela, Lalli, Luca, Di Guardo, Lorenza, Patuzzo, Roberto, Vergani, Barbara, Casiraghi, Elena, Cossa, Mara, Gualeni, Ambra, Bollati, Valentina, Arienti, Flavio, De Braud, Filippo, Mariani, Luigi, Villa, Antonello, Altevogt, Peter, Umansky, Viktor, Rodolfo, Monica, and Rivoltini, Licia

Subjects
Cancer patients -- Care and treatment, Immunotherapy -- Usage, MicroRNA -- Research, Suppressor cells -- Research, Treatment outcome -- Analysis, Cancer treatment, Tumors, Cell death, Infection, Melanoma, Health care industry
Abstract

The accrual of myeloid-derived suppressor cells (MDSCs) represents a major obstacle to effective immunotherapy in cancer patients, but the mechanisms underlying this process in the human setting remain elusive. Here, we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and resistance to treatment with immune checkpoint inhibitors in melanoma patients. The miRs were identified by transcriptional analyses as being responsible for the conversion of monocytes into MDSCs ([CD14.sup.+][HLA-DR.sup.neg] cells) mediated by melanoma extracellular vesicles (EVs) and were shown to recreate MDSC features upon transfection. In melanoma patients, these miRs were increased in circulating [CD14.sup.+] monocytes, plasma, and tumor samples, where they correlated with the myeloid cell infiltrate. In plasma, their baseline levels clustered with the clinical efficacy of CTLA-4 or programmed cell death protein 1 (PD-1) blockade. Hence, MDSC-related miRs represent an indicator of MDSC activity in cancer patients and a potential blood marker of a poor immunotherapy outcome., IntroductionImmunotherapy with immune checkpoint inhibitors (ICIs) has achieved a remarkable improvement in overall survival (OS) in different tumor histologies, albeit the majority of patients display intrinsic resistance (1). The response [...]

Published
2018
Full Text
View/download PDF

10. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

Author

Vergani, Elisabetta, Dugo, Matteo, Cossa, Mara, Frigerio, Simona, Di Guardo, Lorenza, Gallino, Gianfrancesco, Mattavelli, Ilaria, Vergani, Barbara, Lalli, Luca, Tamborini, Elena, Valeri, Barbara, Gargiuli, Chiara, Shahaj, Eriomina, Ferrarini, Marina, Ferrero, Elisabetta, Gomez Lira, Macarena, Huber, Veronica, Del Vecchio, Michele, Sensi, Marialuisa, Leone, Biagio Eugenio, Santinami, Mario, Rivoltini, Licia, Rodolfo, Monica, and Vallacchi, Viviana

Published
2020
Full Text
View/download PDF

11. Supplementary Methods from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Author

Vernieri, Claudio, primary, Fucà, Giovanni, primary, Ligorio, Francesca, primary, Huber, Veronica, primary, Vingiani, Andrea, primary, Iannelli, Fabio, primary, Raimondi, Alessandra, primary, Rinchai, Darawan, primary, Frigè, Gianmaria, primary, Belfiore, Antonino, primary, Lalli, Luca, primary, Chiodoni, Claudia, primary, Cancila, Valeria, primary, Zanardi, Federica, primary, Ajazi, Arta, primary, Cortellino, Salvatore, primary, Vallacchi, Viviana, primary, Squarcina, Paola, primary, Cova, Agata, primary, Pesce, Samantha, primary, Frati, Paola, primary, Mall, Raghvendra, primary, Corsetto, Paola Antonia, primary, Rizzo, Angela Maria, primary, Ferraris, Cristina, primary, Folli, Secondo, primary, Garassino, Marina Chiara, primary, Capri, Giuseppe, primary, Bianchi, Giulia, primary, Colombo, Mario Paolo, primary, Minucci, Saverio, primary, Foiani, Marco, primary, Longo, Valter Daniel, primary, Apolone, Giovanni, primary, Torri, Valter, primary, Pruneri, Giancarlo, primary, Bedognetti, Davide, primary, Rivoltini, Licia, primary, and de Braud, Filippo, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Tables S1-S6, S17-S18 from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Author

Vernieri, Claudio, primary, Fucà, Giovanni, primary, Ligorio, Francesca, primary, Huber, Veronica, primary, Vingiani, Andrea, primary, Iannelli, Fabio, primary, Raimondi, Alessandra, primary, Rinchai, Darawan, primary, Frigè, Gianmaria, primary, Belfiore, Antonino, primary, Lalli, Luca, primary, Chiodoni, Claudia, primary, Cancila, Valeria, primary, Zanardi, Federica, primary, Ajazi, Arta, primary, Cortellino, Salvatore, primary, Vallacchi, Viviana, primary, Squarcina, Paola, primary, Cova, Agata, primary, Pesce, Samantha, primary, Frati, Paola, primary, Mall, Raghvendra, primary, Corsetto, Paola Antonia, primary, Rizzo, Angela Maria, primary, Ferraris, Cristina, primary, Folli, Secondo, primary, Garassino, Marina Chiara, primary, Capri, Giuseppe, primary, Bianchi, Giulia, primary, Colombo, Mario Paolo, primary, Minucci, Saverio, primary, Foiani, Marco, primary, Longo, Valter Daniel, primary, Apolone, Giovanni, primary, Torri, Valter, primary, Pruneri, Giancarlo, primary, Bedognetti, Davide, primary, Rivoltini, Licia, primary, and de Braud, Filippo, primary

Published
2023
Full Text
View/download PDF

13. SupplementaryTables S7-S16 from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Author

Vernieri, Claudio, primary, Fucà, Giovanni, primary, Ligorio, Francesca, primary, Huber, Veronica, primary, Vingiani, Andrea, primary, Iannelli, Fabio, primary, Raimondi, Alessandra, primary, Rinchai, Darawan, primary, Frigè, Gianmaria, primary, Belfiore, Antonino, primary, Lalli, Luca, primary, Chiodoni, Claudia, primary, Cancila, Valeria, primary, Zanardi, Federica, primary, Ajazi, Arta, primary, Cortellino, Salvatore, primary, Vallacchi, Viviana, primary, Squarcina, Paola, primary, Cova, Agata, primary, Pesce, Samantha, primary, Frati, Paola, primary, Mall, Raghvendra, primary, Corsetto, Paola Antonia, primary, Rizzo, Angela Maria, primary, Ferraris, Cristina, primary, Folli, Secondo, primary, Garassino, Marina Chiara, primary, Capri, Giuseppe, primary, Bianchi, Giulia, primary, Colombo, Mario Paolo, primary, Minucci, Saverio, primary, Foiani, Marco, primary, Longo, Valter Daniel, primary, Apolone, Giovanni, primary, Torri, Valter, primary, Pruneri, Giancarlo, primary, Bedognetti, Davide, primary, Rivoltini, Licia, primary, and de Braud, Filippo, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Author

Vernieri, Claudio, primary, Fucà, Giovanni, primary, Ligorio, Francesca, primary, Huber, Veronica, primary, Vingiani, Andrea, primary, Iannelli, Fabio, primary, Raimondi, Alessandra, primary, Rinchai, Darawan, primary, Frigè, Gianmaria, primary, Belfiore, Antonino, primary, Lalli, Luca, primary, Chiodoni, Claudia, primary, Cancila, Valeria, primary, Zanardi, Federica, primary, Ajazi, Arta, primary, Cortellino, Salvatore, primary, Vallacchi, Viviana, primary, Squarcina, Paola, primary, Cova, Agata, primary, Pesce, Samantha, primary, Frati, Paola, primary, Mall, Raghvendra, primary, Corsetto, Paola Antonia, primary, Rizzo, Angela Maria, primary, Ferraris, Cristina, primary, Folli, Secondo, primary, Garassino, Marina Chiara, primary, Capri, Giuseppe, primary, Bianchi, Giulia, primary, Colombo, Mario Paolo, primary, Minucci, Saverio, primary, Foiani, Marco, primary, Longo, Valter Daniel, primary, Apolone, Giovanni, primary, Torri, Valter, primary, Pruneri, Giancarlo, primary, Bedognetti, Davide, primary, Rivoltini, Licia, primary, and de Braud, Filippo, primary

Published
2023
Full Text
View/download PDF

15. Data from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Author

Vernieri, Claudio, primary, Fucà, Giovanni, primary, Ligorio, Francesca, primary, Huber, Veronica, primary, Vingiani, Andrea, primary, Iannelli, Fabio, primary, Raimondi, Alessandra, primary, Rinchai, Darawan, primary, Frigè, Gianmaria, primary, Belfiore, Antonino, primary, Lalli, Luca, primary, Chiodoni, Claudia, primary, Cancila, Valeria, primary, Zanardi, Federica, primary, Ajazi, Arta, primary, Cortellino, Salvatore, primary, Vallacchi, Viviana, primary, Squarcina, Paola, primary, Cova, Agata, primary, Pesce, Samantha, primary, Frati, Paola, primary, Mall, Raghvendra, primary, Corsetto, Paola Antonia, primary, Rizzo, Angela Maria, primary, Ferraris, Cristina, primary, Folli, Secondo, primary, Garassino, Marina Chiara, primary, Capri, Giuseppe, primary, Bianchi, Giulia, primary, Colombo, Mario Paolo, primary, Minucci, Saverio, primary, Foiani, Marco, primary, Longo, Valter Daniel, primary, Apolone, Giovanni, primary, Torri, Valter, primary, Pruneri, Giancarlo, primary, Bedognetti, Davide, primary, Rivoltini, Licia, primary, and de Braud, Filippo, primary

Published
2023
Full Text
View/download PDF

16. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.

Author

Zattarin, Emma, Mariani, Luigi, Menichetti, Alice, Leporati, Rita, Provenzano, Leonardo, Ligorio, Francesca, Fucà, Giovanni, Lobefaro, Riccardo, Lalli, Luca, Vingiani, Andrea, Nichetti, Federico, Griguolo, Gaia, Sirico, Marianna, Bernocchi, Ottavia, Marra, Antonio, Corti, Chiara, Zagami, Paola, Agostinetto, Elisa, Jacobs, Flavia, and Di Mauro, Pierluigi

Abstract

Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2− aBC). Objectives: While CDK4/6i are known to reduce several peripheral blood cells, such as neutrophils, lymphocytes and platelets, the impact of these modulations on clinical outcomes is unknown. Design: A multicenter, retrospective-prospective Italian study. Methods: We investigated the association between baseline peripheral blood cells, or their early modifications (i.e. 2 weeks after treatment initiation), and the progression-free survival (PFS) of HR+/HER2− aBC patients treated with ETs plus CDK4/6i. Random Forest models were used to select covariates associated with patient PFS among a large list of patient- and tumor-related variables. Results: We evaluated 638 HR+/HER2− aBC patients treated with ET plus CDK4/6i at six Italian Institutions between January 2017 and May 2021. High baseline lymphocyte counts were independently associated with longer PFS [median PFS (mPFS) 20.1 versus 13.2 months in high versus low lymphocyte patients, respectively; adjusted Hazard Ratio (aHR): 0.78; 95% confidence interval (CI): 0.66–0.92; p = 0.0144]. Moreover, patients experiencing a lower early reduction of lymphocyte counts had significantly longer PFS when compared to patients undergoing higher lymphocyte decrease (mPFS 18.1 versus 14.5 months; aHR: 0.82; 95% CI: 0.73–0.93; p = 0.0037). Patients with high baseline lymphocytes and undergoing a lower reduction, or even an increase, of lymphocyte counts during CDK4/6i therapy experienced the longest PFS, while patients with lower baseline lymphocytes and undergoing a higher decrease of lymphocytes had the lowest PFS (mPFS 21.4 versus 11 months, respectively). Conclusion: Baseline and on-treatment modifications of peripheral blood lymphocytes have independent prognostic value in HR+/HER2− aBC patients. This study supports the implementation of clinical strategies to boost antitumor immunity in patients with HR+/HER2− aBC treated with ETs plus CDK4/6i. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy

Author

Zattarin, Emma, primary, Sposetti, Caterina, additional, Leporati, Rita, additional, Mariani, Luigi, additional, Menichetti, Alice, additional, Corti, Chiara, additional, Benvenuti, Chiara, additional, Fucà, Giovanni, additional, Lobefaro, Riccardo, additional, Ligorio, Francesca, additional, Presti, Daniele, additional, Provenzano, Leonardo, additional, Vingiani, Andrea, additional, Griguolo, Gaia, additional, Sirico, Marianna, additional, Bernocchi, Ottavia, additional, Marra, Antonio, additional, Zagami, Paola, additional, Agostinetto, Elisa, additional, Jacobs, Flavia, additional, Mauro, Pierluigi Di, additional, Esposito, Andrea, additional, Giorgi, Carlo Alberto, additional, Lalli, Luca, additional, Boldrini, Laura, additional, Giachetti, Pier Paolo Maria Berton, additional, Schianca, Ambra Carnevale, additional, Guarneri, Valentina, additional, Pedersini, Rebecca, additional, Losurdo, Agnese, additional, Zambelli, Alberto, additional, Generali, Daniele Giulio, additional, Curigliano, Giuseppe, additional, Pruneri, Giancarlo, additional, de Braud, Filippo, additional, Dieci, Maria Vittoria, additional, and Vernieri, Claudio, additional

Published
2023
Full Text
View/download PDF

18. A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-URO 8 study).

Author

Verzoni, Elena, primary, Huber, Veronica, additional, Cova, Agata, additional, Squarcina, Paola, additional, Frati, Paola, additional, Lalli, Luca, additional, Stroscia, Martina, additional, Bottiglieri, Achille, additional, Fotia, Giuseppe, additional, Sepe, Pierangela, additional, Stellato, Marco, additional, Zucali, Paolo Andrea, additional, Perrucci, Bruno, additional, Buti, Sebastiano, additional, Maruzzo, Marco, additional, Vittimberga, Isabella, additional, Fornarini, Giuseppe, additional, and Rivoltini, Licia, additional

Published
2023
Full Text
View/download PDF

19. Extracellular vesicles in anti-tumor immunity

Author

Vergani, Elisabetta, primary, Daveri, Elena, additional, Vallacchi, Viviana, additional, Bergamaschi, Laura, additional, Lalli, Luca, additional, Castelli, Chiara, additional, Rodolfo, Monica, additional, Rivoltini, Licia, additional, and Huber, Veronica, additional

Published
2022
Full Text
View/download PDF

20. Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia

Author

Bogani, Giorgio, Lalli, Luca, Sopracordevole, Francesco, Ciavattini, Andrea, Ghelardi, Alessandro, Simoncini, Tommaso, Plotti, Francesco, Casarin, Jvan, Serati, Maurizio, Pinelli, Ciro, Bergamini, Alice, Gardella, Barbara, Dell'Acqua, Andrea, Monti, Ermelinda, Vercellini, Paolo, Palaia, Innocenza, Perniola, Giorgia, Fischetti, Margherita, Santangelo, Giusi, Fracassi, Alice, D'Ippolito, Giovanni, Aguzzoli, Lorenzo, Mandato, Vincenzo Dario, Giannella, Luca, Scaffa, Cono, Falcone, Francesca, Borghi, Chiara, Malzoni, Mario, Giannini, Andrea, Salerno, Maria Giovanna, Liberale, Viola, Contino, Biagio, Donfrancesco, Cristina, Desiato, Michele, Perrone, Anna Myriam, Dondi, Giulia, De Iaco, Pierandrea, Ferrero, Simone, Sarpietro, Giuseppe, Matarazzo, Maria G, Cianci, Antonio, Cianci, Stefano, Bosio, Sara, Ruisi, Simona, Mosca, Lavinia, Tinelli, Raffaele, De Vincenzo, Rosa Pasqualina, Zannoni, Gian Franco, Ferrandina, Maria Gabriella, Petrillo, Marco, Capobianco, Giampiero, Dessiole, Salvatore, Carlea, Annunziata, Zullo, Fulvio, Muschiato, Barbara, Palomba, Stefano, Greggi, Stefano, Spinillo, Arsenio, Ghezzi, Fabio, Colacurci, Nicola, Angioli, Roberto, Benedetti Panici, Pierluigi, Muzii, Ludovico, Scambia, Giovanni, Raspagliesi, Francesco, Di Donato, Violante, De Vincenzo, Rosa (ORCID:0000-0001-7408-0435), Zannoni, Gian Franco (ORCID:0000-0003-1809-129X), Ferrandina, Gabriella (ORCID:0000-0003-4672-4197), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Bogani, Giorgio, Lalli, Luca, Sopracordevole, Francesco, Ciavattini, Andrea, Ghelardi, Alessandro, Simoncini, Tommaso, Plotti, Francesco, Casarin, Jvan, Serati, Maurizio, Pinelli, Ciro, Bergamini, Alice, Gardella, Barbara, Dell'Acqua, Andrea, Monti, Ermelinda, Vercellini, Paolo, Palaia, Innocenza, Perniola, Giorgia, Fischetti, Margherita, Santangelo, Giusi, Fracassi, Alice, D'Ippolito, Giovanni, Aguzzoli, Lorenzo, Mandato, Vincenzo Dario, Giannella, Luca, Scaffa, Cono, Falcone, Francesca, Borghi, Chiara, Malzoni, Mario, Giannini, Andrea, Salerno, Maria Giovanna, Liberale, Viola, Contino, Biagio, Donfrancesco, Cristina, Desiato, Michele, Perrone, Anna Myriam, Dondi, Giulia, De Iaco, Pierandrea, Ferrero, Simone, Sarpietro, Giuseppe, Matarazzo, Maria G, Cianci, Antonio, Cianci, Stefano, Bosio, Sara, Ruisi, Simona, Mosca, Lavinia, Tinelli, Raffaele, De Vincenzo, Rosa Pasqualina, Zannoni, Gian Franco, Ferrandina, Maria Gabriella, Petrillo, Marco, Capobianco, Giampiero, Dessiole, Salvatore, Carlea, Annunziata, Zullo, Fulvio, Muschiato, Barbara, Palomba, Stefano, Greggi, Stefano, Spinillo, Arsenio, Ghezzi, Fabio, Colacurci, Nicola, Angioli, Roberto, Benedetti Panici, Pierluigi, Muzii, Ludovico, Scambia, Giovanni, Raspagliesi, Francesco, Di Donato, Violante, De Vincenzo, Rosa (ORCID:0000-0001-7408-0435), Zannoni, Gian Franco (ORCID:0000-0003-1809-129X), Ferrandina, Gabriella (ORCID:0000-0003-4672-4197), and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

Background: Cervical dysplasia persistence/recurrence has a great impact on women's health and quality of life. In this study, we investigated whether a prognostic nomogram may improve risk assessment after primary conization. Methods: This is a retrospective multi-institutional study based on charts of consecutive patients undergoing conization between 1 January 2010 and 31 December 2014. A nomogram assessing the importance of different variables was built. A cohort of patients treated between 1 January 2015 and 30 June 2016 was used to validate the nomogram. Results: A total of 2966 patients undergoing primary conization were analyzed. The median (range) patient age was 40 (18-89) years. At 5-year of follow-up, 6% of patients (175/2966) had developed a persistent/recurrent cervical dysplasia. Median (range) recurrence-free survival was 18 (5-52) months. Diagnosis of CIN3, presence of HR-HPV types, positive endocervical margins, HPV persistence, and the omission of HPV vaccination after conization increased significantly and independently of the risk of developing cervical dysplasia persistence/recurrence. A nomogram weighting the impact of all variables was built with a C-Index of 0.809. A dataset of 549 patients was used to validate the nomogram, with a C-index of 0.809. Conclusions: The present nomogram represents a useful tool for counseling women about their risk of persistence/recurrence after primary conization. HPV vaccination after conization is associated with a reduced risk of CIN2+.

Published
2022

21. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma

Author

Procopio, Giuseppe, primary, Sepe, Pierangela, additional, Claps, Melanie, additional, Buti, Sebastiano, additional, Colecchia, Maurizio, additional, Giannatempo, Patrizia, additional, Guadalupi, Valentina, additional, Mariani, Luigi, additional, Lalli, Luca, additional, Fucà, Giovanni, additional, de Braud, Filippo, additional, and Verzoni, Elena, additional

Published
2022
Full Text
View/download PDF

23. Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia

Author

Bogani, Giorgio, primary, Lalli, Luca, additional, Sopracordevole, Francesco, additional, Ciavattini, Andrea, additional, Ghelardi, Alessandro, additional, Simoncini, Tommaso, additional, Plotti, Francesco, additional, Casarin, Jvan, additional, Serati, Maurizio, additional, Pinelli, Ciro, additional, Bergamini, Alice, additional, Gardella, Barbara, additional, Dell’Acqua, Andrea, additional, Monti, Ermelinda, additional, Vercellini, Paolo, additional, Palaia, Innocenza, additional, Perniola, Giorgia, additional, Fischetti, Margherita, additional, Santangelo, Giusi, additional, Fracassi, Alice, additional, D’Ippolito, Giovanni, additional, Aguzzoli, Lorenzo, additional, Mandato, Vincenzo Dario, additional, Giannella, Luca, additional, Scaffa, Cono, additional, Falcone, Francesca, additional, Borghi, Chiara, additional, Malzoni, Mario, additional, Giannini, Andrea, additional, Salerno, Maria Giovanna, additional, Liberale, Viola, additional, Contino, Biagio, additional, Donfrancesco, Cristina, additional, Desiato, Michele, additional, Perrone, Anna Myriam, additional, Dondi, Giulia, additional, De Iaco, Pierandrea, additional, Ferrero, Simone, additional, Sarpietro, Giuseppe, additional, Matarazzo, Maria G., additional, Cianci, Antonio, additional, Cianci, Stefano, additional, Bosio, Sara, additional, Ruisi, Simona, additional, Mosca, Lavinia, additional, Tinelli, Raffaele, additional, De Vincenzo, Rosa, additional, Zannoni, Gian Franco, additional, Ferrandina, Gabriella, additional, Petrillo, Marco, additional, Capobianco, Giampiero, additional, Dessiole, Salvatore, additional, Carlea, Annunziata, additional, Zullo, Fulvio, additional, Muschiato, Barbara, additional, Palomba, Stefano, additional, Greggi, Stefano, additional, Spinillo, Arsenio, additional, Ghezzi, Fabio, additional, Colacurci, Nicola, additional, Angioli, Roberto, additional, Benedetti Panici, Pierluigi, additional, Muzii, Ludovico, additional, Scambia, Giovanni, additional, Raspagliesi, Francesco, additional, and Di Donato, Violante, additional

Published
2022
Full Text
View/download PDF

26. Low baseline neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict increased overall survival in locally recurrent rectal cancer despite R1 margins

Author

Daveri, Elena, primary, Sorrentino, Luca, additional, Lalli, Luca, additional, Guaglio, Marcello, additional, Battaglia, Luigi, additional, Cattaneo, Laura, additional, Sabella, Giovanna, additional, Milione, Massimo, additional, Rivoltini, Licia, additional, Cosimelli, Maurizio, additional, and Belli, Filiberto, additional

Published
2022
Full Text
View/download PDF

28. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

Author

Vernieri, Claudio, primary, Fucà, Giovanni, additional, Ligorio, Francesca, additional, Huber, Veronica, additional, Vingiani, Andrea, additional, Iannelli, Fabio, additional, Raimondi, Alessandra, additional, Rinchai, Darawan, additional, Frigè, Gianmaria, additional, Belfiore, Antonino, additional, Lalli, Luca, additional, Chiodoni, Claudia, additional, Cancila, Valeria, additional, Zanardi, Federica, additional, Ajazi, Arta, additional, Cortellino, Salvatore, additional, Vallacchi, Viviana, additional, Squarcina, Paola, additional, Cova, Agata, additional, Pesce, Samantha, additional, Frati, Paola, additional, Mall, Raghvendra, additional, Corsetto, Paola Antonia, additional, Rizzo, Angela Maria, additional, Ferraris, Cristina, additional, Folli, Secondo, additional, Garassino, Marina Chiara, additional, Capri, Giuseppe, additional, Bianchi, Giulia, additional, Colombo, Mario Paolo, additional, Minucci, Saverio, additional, Foiani, Marco, additional, Longo, Valter Daniel, additional, Apolone, Giovanni, additional, Torri, Valter, additional, Pruneri, Giancarlo, additional, Bedognetti, Davide, additional, Rivoltini, Licia, additional, and de Braud, Filippo, additional

Published
2021
Full Text
View/download PDF

30. The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients

Author

Paolino, Giovanni, primary, Huber, Veronica, additional, Camerini, Serena, additional, Casella, Marialuisa, additional, Macone, Alberto, additional, Bertuccini, Lucia, additional, Iosi, Francesca, additional, Moliterni, Elisa, additional, Cecchetti, Serena, additional, Ruspantini, Irene, additional, Chiarotti, Flavia, additional, Vergani, Elisabetta, additional, Lalli, Luca, additional, Raggi, Carla, additional, Di Biase, Antonella, additional, Calvieri, Stefano, additional, Mercuri, Santo Raffaele, additional, Lugini, Luana, additional, and Federici, Cristina, additional

Published
2021
Full Text
View/download PDF

31. Finding a rIsk assessmeNt moDel for thromboembolic events in hospItalized Cancer pATiEnts: the INDICATE study running title: thromboembolism in hospitalized cancer patients

Author

Nichetti, Federico, primary, Ligorio, Francesca, additional, Montelatici, Giulia, additional, Porcu, Luca, additional, Zattarin, Emma, additional, Provenzano, Leonardo, additional, Franza, Andrea, additional, Lalli, Luca, additional, De Braud, Filippo, additional, and Platania, Marco, additional

Published
2021
Full Text
View/download PDF

32. Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients

Author

Rinchai, Darawan, primary, Verzoni, Elena, additional, Huber, Veronica, additional, Cova, Agata, additional, Squarcina, Paola, additional, De Cecco, Loris, additional, Braud, Filippo, additional, Ratta, Raffaele, additional, Dugo, Matteo, additional, Lalli, Luca, additional, Vallacchi, Viviana, additional, Rodolfo, Monica, additional, Roelands, Jessica, additional, Castelli, Chiara, additional, Chaussabel, Damien, additional, Procopio, Giuseppe, additional, Bedognetti, Davide, additional, and Rivoltini, Licia, additional

Published
2021
Full Text
View/download PDF

33. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)

Author

Vernieri, Claudio, primary, Nichetti, Federico, additional, Lalli, Luca, additional, Moscetti, Luca, additional, Giorgi, Carlo Alberto, additional, Griguolo, Gaia, additional, Marra, Antonio, additional, Randon, Giovanni, additional, Rea, Carmen G., additional, Ligorio, Francesca, additional, Scagnoli, Simone, additional, De Angelis, Claudia, additional, Molinelli, Chiara, additional, Fabbri, Agnese, additional, Ferraro, Emanuela, additional, Trapani, Dario, additional, Milani, Andrea, additional, Agostinetto, Elisa, additional, Bernocchi, Ottavia, additional, Catania, Giovanna, additional, Vantaggiato, Amelia, additional, Palleschi, Michela, additional, Moretti, Anna, additional, Basile, Debora, additional, Cinausero, Marika, additional, Ajazi, Arta, additional, Castagnoli, Lorenzo, additional, Lo Vullo, Salvatore, additional, Gerratana, Lorenzo, additional, Puglisi, Fabio, additional, La Verde, Nicla, additional, Arpino, Grazia, additional, Rocca, Andrea, additional, Ciccarese, Mariangela, additional, Pedersini, Rebecca, additional, Fabi, Alessandra, additional, Generali, Daniele, additional, Losurdo, Agnese, additional, Montemurro, Filippo, additional, Curigliano, Giuseppe, additional, Del Mastro, Lucia, additional, Michelotti, Andrea, additional, Cortesi, Enrico, additional, Guarneri, Valentina, additional, Pruneri, Giancarlo, additional, Mariani, Luigi, additional, and de Braud, Filippo, additional

Published
2021
Full Text
View/download PDF

34. Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients

Author

Huber, Veronica, primary, Di Guardo, Lorenza, additional, Lalli, Luca, additional, Giardiello, Daniele, additional, Cova, Agata, additional, Squarcina, Paola, additional, Frati, Paola, additional, Di Giacomo, Anna Maria, additional, Pilla, Lorenzo, additional, Tazzari, Marcella, additional, Camisaschi, Chiara, additional, Arienti, Flavio, additional, Castelli, Chiara, additional, Rodolfo, Monica, additional, Beretta, Valeria, additional, Di Nicola, Massimo, additional, Maio, Michele, additional, Del Vecchio, Michele, additional, de Braud, Filippo, additional, Mariani, Luigi, additional, and Rivoltini, Licia, additional

Published
2021
Full Text
View/download PDF

35. Additional file 3 of miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

Author

Vergani, Elisabetta, Dugo, Matteo, Cossa, Mara, Frigerio, Simona, Di Guardo, Lorenza, Gallino, Gianfrancesco, Mattavelli, Ilaria, Vergani, Barbara, Lalli, Luca, Tamborini, Elena, Valeri, Barbara, Gargiuli, Chiara, Shahaj, Eriomina, Ferrarini, Marina, Ferrero, Elisabetta, Gomez Lira, Macarena, Huber, Veronica, Del Vecchio, Michele, Sensi, Marialuisa, Leone, Biagio Eugenio, Santinami, Mario, Rivoltini, Licia, Rodolfo, Monica, and Vallacchi, Viviana

Abstract

Additional file 2: Supplementary Fig. S1. Altered miR-146a expression influences BRAF/MEKi sensitivity and apoptosis in melanoma. A) Boxplots representing IC50 values of 6 matched PLX4032-resistant (R) and sensitive (S) melanoma cell lines to PLX4032 (vemurafenib), BRAFi (dabrafenib), MEKi (trametinib), to the combined treatment BRAF/MEKi, and to sTRAIL-induced apoptosis. B) Inverse correlation between miR-146a expression levels and IC50 values of PLX4032, BRAFi and MEKi in melanoma cell lines (Spearman analysis). C) Forced expression of miR-146a (+m-miR-146a) in LM16R cell line and in LM69 and LM70 short term cultures increased the effects of PLX4032 treatment as shown by reduced cell growth and increased cell cytotoxicity and apoptosis, evaluated by CCK8, LDH and caspase 8 and 3/7 activity. D) Inhibition of miR-146a expression (i-miR-146a) in LM16 cells increased cell proliferation and decreased the release of LDH and the apoptosis rate as evaluated by CCK8, LDH and caspase 3/7 activity. E) Overexpression of miR-146a (m-miR-146a) upon PLX4032, BRAF/MEKi and sTRAIL treatments in LM47R cells increased cell cytotoxicity and apoptosis, as evaluated by LDH and caspase 8 and 3/7 activity. Data are plotted compared to scrambled control. *: p < 0.05, **: p < 0.01, ***: p < 0.0001 by Student’s unpaired t test. Supplementary Fig. S2. COX2 inhibition increases sensitivity to PLX4032 and to BRAF/MEKi and reduces PGE2 release. A) Relative luciferase activity after co-transfection of PTGS2 3’UTR luciferase reporter vector or control vector with miR-146a mimic or mimic negative control. Experiment was performed in LM16R cells. B) Inverse correlation between miR-146a expression levels and IC50 values of PLX4032 in melanoma cell lines (Spearman analysis). C) Western blot analyses showing downregulation of COX2 after transfection with siRNA against COX2 (siCOX2) compared to scrambled control (S). COX2 protein levels were downregulated to 15%, as determined by quantification of the signal and expressed as the ratio of COX2/Actin intensity. Experiment was performed with LM47R cells. D) Silencing of COX2 by siRNA transfection enhanced cell growth inhibition and increased cell cytotoxicity and apoptosis upon treatment with PLX4032 compared to scrambled control. E) PGE2 release in culture supernatants following 24 h treatment with the COX2 inhibitors celecoxib and NS398, alone or in combination with BRAF/MEKi. F) Combined treatment with celecoxib increased cell growth inhibition and cytotoxicity by PLX4032. ●: interaction index = 1. G) Dose-dependent effect of celecoxib alone (5, 10, 20, 40, 50 and 80 μM) and combined with PLX4032 (3 μM) on cell growth. ●: interaction index = 1 at the dose of 50 μM of celecoxib combined with PLX4032. P values were calculated by Student’s unpaired t test in A, D and F, by one-way ANOVA followed by Bonferroni correction in E, and by two-way ANOVA followed by Bonferroni correction in G. *: p < 0.05, **: p < 0.01, ***: p < 0.0001. Supplementary Fig. S3. miR-146a expression levels are inversely correlated with levels of target genes. Analysis of correlation between miR-146a expression and its target genes EGFR, CCL2 and BCL2L1 in metastatic melanoma specimens. The rp and p values resulting from Pearson analysis are shown. Supplementary Fig. S4. Dynamic culture in bioreactor preserves TME architecture of 3D tumor explants. Representative histological images of H&E-stained 3D tumor sections after 3 days culture in bioreactor. The marked areas in the left panels are shown at higher magnification in the right panels to display the preserved cellularity and tumor tissue histo-architecture. Scale bar 80 μM. Supplementary Fig. S5. miR-146a overexpression increases drug sensitivity in 3D cultures of tumor explants. A) Modulation of direct and indirect miR-146a target genes upon transfection of miR-146a mimic (m-miR-146a) compared to scrambled-transfected control (S) in 3D cultures of BRAF-mutated melanoma tumors from naïve patients. AU: arbitrary units. B) Decreased staining for Ki67 and pERK proliferating cells and increased Caspase 3 positive cells in 3D cultures upon treatment with BRAF/MEKi and transfection with miR-146a (m-miR-146a) or scrambled control (S). Scale bar 10 um.

Published
2020
Full Text
View/download PDF

36. Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity

Author

Rinchai, Darawan, primary, Verzoni, Elena, additional, Huber, Veronica, additional, Cova, Agata, additional, Squarcina, Paola, additional, De Cecco, Loris, additional, de Braud, Filippo, additional, Ratta, Raffaele, additional, Dugo, Matteo, additional, Lalli, Luca, additional, Vallacchi, Viviana, additional, Rodolfo, Monica, additional, Roelands, Jessica, additional, Castelli, Chiara, additional, Chaussabel, Damien, additional, Procopio, Giuseppe, additional, Bedognetti, Davide, additional, and Rivoltini, Licia, additional

Published
2020
Full Text
View/download PDF

37. Selective modulation of immune transcripts in extracellular vesicles from plasma of renal cell carcinoma patients receiving nivolumab.

Author

Verzoni, Elena, primary, Shahaj, Eriomina, additional, Frigerio, Simona, additional, Cova, Agata, additional, Squarcina, Paola, additional, Pesce, Samantha, additional, Vergani, Elisabetta, additional, Vallacchi, Viviana, additional, Lalli, Luca, additional, Pietrantonio, Filippo, additional, Di Nicola, Massimo A., additional, Procopio, Giuseppe, additional, De Braud, Filippo G., additional, Mennitto, Alessia, additional, Claps, Melanie, additional, Sepe, Pierangela, additional, Rodolfo, Monica, additional, Rivoltini, Licia, additional, and Huber, Veronica, additional

Published
2020
Full Text
View/download PDF

38. FNA and CNB in the Diagnosis of Pulmonary Lesions: A Single-center Experience on 665 Patients, Comparison between Two Periods

Author

Marchianò, Alfonso Vittorio, primary, Cosentino, Maria, additional, Di Tolla, Giuseppe, additional, Greco, Francesca Gabriella, additional, Silva, Mario, additional, Sverzellati, Nicola, additional, Fabbri, Alessandra, additional, Tamborini, Elena, additional, Russo, Giuseppe Lo, additional, Mariani, Luigi, additional, Lalli, Luca, additional, and Pastorino, Ugo, additional

Published
2017
Full Text
View/download PDF

45. Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients

Author

Rinchai, Darawan, Verzoni, Elena, Huber, Veronica, Cova, Agata, Squarcina, Paola, De Cecco, Loris, Braud, Filippo, Ratta, Raffaele, Dugo, Matteo, Lalli, Luca, Vallacchi, Viviana, Rodolfo, Monica, Roelands, Jessica, Castelli, Chiara, Chaussabel, Damien, Procopio, Giuseppe, Bedognetti, Davide, and Rivoltini, Licia

Subjects
Male, Medicine (General), renal cell carcinoma, Indazoles, blood transcriptomic profile, cancer biomarkers, Angiogenesis Inhibitors, Immunomodulation, R5-920, immunomonitoring, tyrosine kinase inhibitors, Biomarkers, Tumor, Tumor Cells, Cultured, Tumor Microenvironment, pazopanib, Humans, Carcinoma, Renal Cell, Research Articles, Aged, myeloid‐derived suppressor cells, Sulfonamides, immunosuppression, transcriptional modular repertoire analysis, Myeloid-Derived Suppressor Cells, bioinformatics, Prognosis, Kidney Neoplasms, Gene Expression Regulation, Neoplastic, Survival Rate, antiangiogenics, Pyrimidines, Female, immunotherapy, Transcriptome, Follow-Up Studies, Research Article
Abstract

Background The combination of immune checkpoint blockade (ICB) with standard therapies is becoming a common approach for overcoming resistance to cancer immunotherapy in most human malignancies including metastatic renal cell carcinoma (mRCC). In this regard, insights into the immunomodulatory properties of antiangiogenic agents may help designing multidrug schedules based on specific immune synergisms. Methods We used orthogonal transcriptomic and phenotyping platforms combined with functional analytic pipelines to elucidate the immunomodulatory effect of the antiangiogenic agent pazopanib in mRCC patients. Nine patients were studied longitudinally over a period of 6 months. We also analyzed transcriptional data from The Cancer Genome Atlas (TCGA) RCC cohort (N = 571) to assess the prognostic implications of our findings. The effect of pazopanib was assessed in vitro on NK cells and T cells. Additionally, myeloid‐derived suppressor (MDSC)‐like cells were generated from CD14+ monocytes transfected with mimics of miRNAs associated with MDSC function in the presence or absence of pazopanib. Results Pazopanib administration caused a rapid and dramatic reshaping in terms of frequency and transcriptional activity of multiple blood immune cell subsets, with a downsizing of MDSC and regulatory T cells in favor of a strong enhancement in PD‐1 expressing cytotoxic T and Natural Killer effectors. These changes were paired with an increase of the expression of transcripts reflecting activation of immune‐effector functions. This immunomodulation was marked but transient, peaking at the third month of treatment. Moreover, the intratumoral expression level of a MDSC signature (MDSC INT) was strongly associated with poor prognosis in RCC patients. In vitro experiments indicate that the observed immunomodulation might be due to an inhibitory effect on MDSC‐mediated suppression, rather than a direct effect on NK and T cells. Conclusions The marked but transient nature of this immunomodulation, peaking at the third month of treatment, provides the rationale for the use of antiangiogenics as a preconditioning strategy to improve the efficacy of ICB.

Full Text
View/download PDF

46. Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia

Author

Giorgio Bogani, Luca Lalli, Francesco Sopracordevole, Andrea Ciavattini, Alessandro Ghelardi, Tommaso Simoncini, Francesco Plotti, Jvan Casarin, Maurizio Serati, Ciro Pinelli, Alice Bergamini, Barbara Gardella, Andrea Dell’Acqua, Ermelinda Monti, Paolo Vercellini, Innocenza Palaia, Giorgia Perniola, Margherita Fischetti, Giusi Santangelo, Alice Fracassi, Giovanni D’Ippolito, Lorenzo Aguzzoli, Vincenzo Dario Mandato, Luca Giannella, Cono Scaffa, Francesca Falcone, Chiara Borghi, Mario Malzoni, Andrea Giannini, Maria Giovanna Salerno, Viola Liberale, Biagio Contino, Cristina Donfrancesco, Michele Desiato, Anna Myriam Perrone, Giulia Dondi, Pierandrea De Iaco, Simone Ferrero, Giuseppe Sarpietro, Maria G. Matarazzo, Antonio Cianci, Stefano Cianci, Sara Bosio, Simona Ruisi, Lavinia Mosca, Raffaele Tinelli, Rosa De Vincenzo, Gian Franco Zannoni, Gabriella Ferrandina, Marco Petrillo, Giampiero Capobianco, Salvatore Dessiole, Annunziata Carlea, Fulvio Zullo, Barbara Muschiato, Stefano Palomba, Stefano Greggi, Arsenio Spinillo, Fabio Ghezzi, Nicola Colacurci, Roberto Angioli, Pierluigi Benedetti Panici, Ludovico Muzii, Giovanni Scambia, Francesco Raspagliesi, Violante Di Donato, Bogani, G., Lalli, L., Sopracordevole, F., Ciavattini, A., Ghelardi, A., Simoncini, T., Plotti, F., Casarin, J., Serati, M., Pinelli, C., Bergamini, A., Gardella, B., Dell'Acqua, A., Monti, E., Vercellini, P., Palaia, I., Perniola, G., Fischetti, M., Santangelo, G., Fracassi, A., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Giannella, L., Scaffa, C., Falcone, F., Borghi, C., Malzoni, M., Giannini, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., Dondi, G., De Iaco, P., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Cianci, S., Bosio, S., Ruisi, S., Mosca, L., Tinelli, R., De Vincenzo, R., Zannoni, G. F., Ferrandina, G., Petrillo, M., Capobianco, G., Dessiole, S., Carlea, A., Zullo, F., Muschiato, B., Palomba, S., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Angioli, R., Panici, P. B., Muzii, L., Scambia, G., Raspagliesi, F., Di Donato, V., Bogani, Giorgio, Lalli, Luca, Sopracordevole, Francesco, Ciavattini, Andrea, Ghelardi, Alessandro, Simoncini, Tommaso, Plotti, Francesco, Casarin, Jvan, Serati, Maurizio, Pinelli, Ciro, Bergamini, Alice, Gardella, Barbara, Dell'Acqua, Andrea, Monti, Ermelinda, Vercellini, Paolo, Palaia, Innocenza, Perniola, Giorgia, Fischetti, Margherita, Santangelo, Giusi, Fracassi, Alice, D'Ippolito, Giovanni, Aguzzoli, Lorenzo, Mandato, Vincenzo Dario, Giannella, Luca, Scaffa, Cono, Falcone, Francesca, Borghi, Chiara, Malzoni, Mario, Giannini, Andrea, Salerno, Maria Giovanna, Liberale, Viola, Contino, Biagio, Donfrancesco, Cristina, Desiato, Michele, Perrone, Anna Myriam, Dondi, Giulia, De Iaco, Pierandrea, Ferrero, Simone, Sarpietro, Giuseppe, Matarazzo, Maria G, Cianci, Antonio, Cianci, Stefano, Bosio, Sara, Ruisi, Simona, Mosca, Lavinia, Tinelli, Raffaele, De Vincenzo, Rosa, Zannoni, Gian Franco, Ferrandina, Gabriella, Petrillo, Marco, Capobianco, Giampiero, Dessiole, Salvatore, Carlea, Annunziata, Zullo, Fulvio, Muschiato, Barbara, Palomba, Stefano, Greggi, Stefano, Spinillo, Arsenio, Ghezzi, Fabio, Colacurci, Nicola, Angioli, Roberto, Benedetti Panici, Pierluigi, Muzii, Ludovico, Scambia, Giovanni, Raspagliesi, Francesco, and Di Donato, Violante

Subjects
Pharmacology, conization, HPV, Settore MED/40 - GINECOLOGIA E OSTETRICIA, recurrence, Infectious Diseases, Drug Discovery, Immunology, LEEP, Pharmacology (medical), cervical dysplasia
Abstract

Background: Cervical dysplasia persistence/recurrence has a great impact on women’s health and quality of life. In this study, we investigated whether a prognostic nomogram may improve risk assessment after primary conization. Methods: This is a retrospective multi-institutional study based on charts of consecutive patients undergoing conization between 1 January 2010 and 31 December 2014. A nomogram assessing the importance of different variables was built. A cohort of patients treated between 1 January 2015 and 30 June 2016 was used to validate the nomogram. Results: A total of 2966 patients undergoing primary conization were analyzed. The median (range) patient age was 40 (18–89) years. At 5-year of follow-up, 6% of patients (175/2966) had developed a persistent/recurrent cervical dysplasia. Median (range) recurrence-free survival was 18 (5–52) months. Diagnosis of CIN3, presence of HR-HPV types, positive endocervical margins, HPV persistence, and the omission of HPV vaccination after conization increased significantly and independently of the risk of developing cervical dysplasia persistence/recurrence. A nomogram weighting the impact of all variables was built with a C-Index of 0.809. A dataset of 549 patients was used to validate the nomogram, with a C-index of 0.809. Conclusions: The present nomogram represents a useful tool for counseling women about their risk of persistence/recurrence after primary conization. HPV vaccination after conization is associated with a reduced risk of CIN2+.

Published
2022

47. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)

Author

Giovanna Catania, Fabio Puglisi, Dario Trapani, Federico Nichetti, Lorenzo Gerratana, Alessandra Fabi, Marika Cinausero, Michela Palleschi, Agnese Losurdo, Filippo Montemurro, Enrico Cortesi, Rebecca Pedersini, Andrea Rocca, Carlo Alberto Giorgi, Grazia Arpino, Gaia Griguolo, Lorenzo Castagnoli, Giancarlo Pruneri, Andrea Michelotti, Giuseppe Curigliano, Valentina Guarneri, Francesca Ligorio, Giovanni Randon, Daniele Generali, Emanuela Ferraro, Luca Moscetti, A. Fabbri, Arta Ajazi, Elisa Agostinetto, Claudia De Angelis, Amelia Vantaggiato, Carmen G. Rea, Antonio Marra, Filippo de Braud, Nicla La Verde, Debora Basile, Lucia Del Mastro, Luigi Mariani, Salvatore Lo Vullo, Mariangela Ciccarese, Anna Moretti, Simone Scagnoli, Claudio Vernieri, Ottavia Bernocchi, Chiara Molinelli, Andrea Milani, Luca Lalli, Vernieri, C., Nichetti, F., Lalli, L., Moscetti, L., Giorgi, C. A., Griguolo, G., Marra, A., Randon, G., Rea, C. G., Ligorio, F., Scagnoli, S., De Angelis, C., Molinelli, C., Fabbri, A., Ferraro, E., Trapani, D., Milani, A., Agostinetto, E., Bernocchi, O., Catania, G., Vantaggiato, A., Palleschi, M., Moretti, A., Basile, D., Cinausero, M., Ajazi, A., Castagnoli, L., Vullo, S. L., Gerratana, L., Puglisi, F., La Verde, N., Arpino, G., Rocca, A., Ciccarese, M., Pedersini, R., Fabi, A., Generali, D., Losurdo, A., Montemurro, F., Curigliano, G., Del Mastro, L., Michelotti, A., Cortesi, E., Guarneri, V., Pruneri, G., Mariani, L., De Braud, F., Vernieri, Claudio, Nichetti, Federico, Lalli, Luca, Moscetti, Luca, Giorgi, Carlo Alberto, Griguolo, Gaia, Marra, Antonio, Randon, Giovanni, Rea, Carmen G, Ligorio, Francesca, Scagnoli, Simone, De Angelis, Claudia, Molinelli, Chiara, Fabbri, Agnese, Ferraro, Emanuela, Trapani, Dario, Milani, Andrea, Agostinetto, Elisa, Bernocchi, Ottavia, Catania, Giovanna, Vantaggiato, Amelia, Palleschi, Michela, Moretti, Anna, Basile, Debora, Cinausero, Marika, Ajazi, Arta, Castagnoli, Lorenzo, Lo Vullo, Salvatore, Gerratana, Lorenzo, Puglisi, Fabio, La Verde, Nicla, Arpino, Grazia, Rocca, Andrea, Ciccarese, Mariangela, Pedersini, Rebecca, Fabi, Alessandra, Generali, Daniele, Losurdo, Agnese, Montemurro, Filippo, Curigliano, Giuseppe, Del Mastro, Lucia, Michelotti, Andrea, Cortesi, Enrico, Guarneri, Valentina, Pruneri, Giancarlo, Mariani, Luigi, and de Braud, Filippo

Subjects
0301 basic medicine, Oncology, Blood Glucose, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, metabolism everolimus, chemistry.chemical_compound, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, ErbB-2, Exemestane, Retrospective Studie, Antineoplastic Combined Chemotherapy Protocols, Receptors, Hyperinsulinemia, drug therapy breast neoplasms, Receptors, Estrogen, Hormone receptor, 030220 oncology & carcinogenesis, Female, Breast Neoplasm, medicine.drug, Receptor, Human, medicine.medical_specialty, medicine.drug_class, Breast Neoplasms, genetics breast neoplasms, 03 medical and health sciences, Diabetes mellitus, Internal medicine, medicine, Humans, Everolimus, Retrospective Studies, Aromatase inhibitor, Antineoplastic Combined Chemotherapy Protocol, blood glucose breast neoplasms, Androstadiene, business.industry, Insulin, Cancer, medicine.disease, Estrogen, Androstadienes, 030104 developmental biology, chemistry, Phosphatidylinositol 3-Kinase, business
Abstract

Purpose: The mTOR complex C1 (mTORC1) inhibitor everolimus in combination with the aromatase inhibitor exemestane is an effective treatment for patients with hormone receptor—positive (HR+), HER2-negative (HER2−), advanced breast cancer (HR+/HER2− aBC). However, everolimus can cause hyperglycemia and hyperinsulinemia, which could reactivate the PI3K/protein kinase B (AKT)/mTORC1 pathway and induce tumor resistance to everolimus. Experimental Design: We conducted a multicenter, retrospective, Italian study to investigate the impact of baseline and on-treatment (i.e., during first 3 months of therapy) blood glucose levels on progression-free survival (PFS) in patients with HR+/HER2− aBC treated with everolimus-exemestane. Results: We evaluated 809 patients with HR+/HER2− aBC treated with everolimus-exemestane as any line of therapy for advanced disease. When evaluated as dichotomous variables, baseline and on-treatment glycemia were not significantly associated with PFS. However, when blood glucose concentration was evaluated as a continuous variable, a multivariable model accounting for clinically relevant patient- and tumor-related variables revealed that both baseline and on-treatment glycemia are associated with PFS, and this association is largely attributable to their interaction. In particular, patients who are normoglycemic at baseline and experience on-treatment diabetes have lower PFS compared with patients who are already hyperglycemic at baseline and experience diabetes during everolimus-exemestane therapy (median PFS, 6.34 vs. 10.32 months; HR, 1.76; 95% confidence interval, 1.15–2.69; P = 0.008). Conclusions: The impact of on-treatment glycemia on the efficacy of everolimus-exemestane therapy in patients with HR+/HER2− aBC depends on baseline glycemia. This study lays the foundations for investigating novel therapeutic approaches to target the glucose/insulin axis in combination with PI3K/AKT/mTORC1 inhibitors in patients with HR+/HER2− aBC.

Published
2021

49. Predicting the Risk of nOdal disease with histological and Molecular features in Endometrial cancer: the prospective PROME trial.

Author

Bogani G, Lalli L, Casarin J, Ghezzi F, Chiappa V, Fanfani F, Scambia G, and Raspagliesi F

Subjects
Humans, Female, Middle Aged, Prospective Studies, Aged, Adult, Neoplasm Staging, Sentinel Lymph Node Biopsy, Aged, 80 and over, Lymph Nodes pathology, Lymph Nodes surgery, Carcinoma, Endometrioid pathology, Carcinoma, Endometrioid genetics, Carcinoma, Endometrioid surgery, Tumor Suppressor Protein p53 genetics, Endometrial Neoplasms pathology, Endometrial Neoplasms genetics, Endometrial Neoplasms surgery, Lymphatic Metastasis
Abstract

Objective: To assess the role of histopathological and molecular features in predicting the risk of nodal metastases in apparent early-stage endometrial cancer patients undergoing sentinel node mapping., Methods: This is a prospective trial. Consecutive patients with apparent early-stage endometrial cancer, undergoing laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and sentinel node mapping, were enrolled. Histological and molecular features were used to predict the node positivity., Results: Charts of 223 apparent early-stage endometrial cancer patients were included in this study. Four (1.8%) patients were excluded from this study due to the lack of data about molecular features. Additionally, nine (4%) patients did not meet the inclusion criteria (due to the presence of peritoneal carcinomatosis or bulky nodes (the presence of p53 abnormality correlated with the presence of advanced stage disease (p<0.001)). The study population included 178 (84.8%) and 32 (15.2%) patients with endometrioid and non-endometrioid endometrial cancer, respectively. According to pathological uterine risk factors, 93 (44.3%), 45 (21.4%), 40 (19.1%), and 32 (15.2%) were classified as low, intermediate, intermediate-high, and high-risk, respectively. Using the surrogate molecular classification, 10 (4.8%), 42 (20%), 57 (27.1%), and 101 (48.1%) were included in the POLE mutated, p53 abnormal, MMRd/MSI-H, and NSMP, respectively. Overall, 41 (19.5%) patients were detected with positive nodes. Molecular features were not associated with the risk of having nodal metastases (OR 1.03, 95% CI 0.21 to 5.05, p=0.969 for POLE mutated; OR 0.788, 95% CI 0.32 to 1.98, p=0.602 for p53 abnormal; OR 1.14, 95% CI 0.53 to 2.42, p=0.733 for MMRd/MSI-H). At multivariable analysis, only deep myometrial invasion (OR 3.318, 95% CI 1.357 to 8.150, p=0.009) and lymphovascular space invasion (OR 6.584, 95% CI 2.663 to 16.279, p<0.001) correlated with the increased risk of positive nodes., Conclusion: Our data suggest that molecular classification does not seem useful to tailor the need of nodal dissection in apparent early-stage endometrial cancer. p53 abnormality predicts the risk of having advanced disease at presentation. Further external validation is needed., Clinical Trial Registration: NCT05793333., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results